Free Trial

Anixa Biosciences (ANIX) News Today

Anixa Biosciences logo
$2.94 0.00 (0.00%)
(As of 12/11/2024 ET)
Anixa Biosciences, Inc. stock logo
Anixa Biosciences' (ANIX) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday.
Anixa Biosciences initiates third cohort in CAR-T clinical trial
Anixa Hikes on Tests
Anixa Biosciences, Inc. stock logo
Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 28.9% in October
Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 421,900 shares, a decline of 28.9% from the October 15th total of 593,700 shares. Based on an average daily volume of 75,800 shares, the short-interest ratio is presently 5.6 days. Approximately 1.4% of the company's shares are sold short.
Anixa Biosciences Reports Promising Phase 1 Vaccine Results
Anixa Biosciences, Inc. stock logo
Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 8.9% in September
Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large drop in short interest in September. As of September 30th, there was short interest totalling 627,200 shares, a drop of 8.9% from the September 15th total of 688,800 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average daily volume of 96,300 shares, the short-interest ratio is currently 6.5 days.
Anixa Biosciences, Inc. stock logo
Anixa Biosciences, Inc. (NASDAQ:ANIX) Expected to Post FY2024 Earnings of ($0.42) Per Share
Anixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Anixa Biosciences in a research report issued on Monday, September 16th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.42) p
Anixa Biosciences, Inc. stock logo
Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday.
Anixa Biosciences, Inc. stock logo
Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Beats Estimates By $0.01 EPS
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01.
Anixa Biosciences, Inc. stock logo
Anixa Biosciences (NASDAQ:ANIX) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. I
EF Hutton Acquisition Co. I raised Anixa Biosciences to a "strong-buy" rating in a research note on Wednesday.
Anixa Biosciences, Inc. stock logo
Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Acquires 21,646 Shares
Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 21,646 shares of the company's stock in a transaction that occurred on Tuesday, July 30th. The stock was acquired at an average price of $3.06 per share, with a total value of $66,236.76. Following the acquisition, the director now owns 890,754 shares in the company, valued at $2,725,707.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Anixa Biosciences, Inc. stock logo
Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $15,450.00 in Stock
Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies bought 5,000 shares of the firm's stock in a transaction on Friday, July 26th. The stock was acquired at an average cost of $3.09 per share, with a total value of $15,450.00. Following the completion of the purchase, the director now owns 115,000 shares of the company's stock, valued at approximately $355,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Anixa Biosciences, Inc. stock logo
HC Wainwright Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)
HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Wednesday.
Get Anixa Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.

Download Now: The Book That Could Make You A Millionaire (Ad)

Bestselling Crypto Book 80% Off Crypto millionaire reveals how you could make a fortune in crypto with as little as $50

Download your digital copy now

ANIX Media Mentions By Week

ANIX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ANIX
News Sentiment

0.57

0.81

Average
Medical
News Sentiment

ANIX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ANIX Articles
This Week

3

2

ANIX Articles
Average Week

Get Anixa Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ANIX) was last updated on 12/12/2024 by MarketBeat.com Staff
From Our Partners